On the 12th, SK Bioscience made a public announcement regarding the results of Phase III clinical trial that investigated the use of its SKYCovione (GBP510) as a booster shot. Results showed that the vaccine demonstrated significantly high neutralizing antibody titers as a booster shot.

On the same day, SK Bioscience announced the two top-line results of a global Phase III trial of SKYCovione as a booster shot. The clinical trial was conducted on 450 adults aged 18 or older at 17 domestic and foreign institutions including Korea University Guro Hospital.

The trial compared the neutralizing antibody titers of people who received an additional dose of SKYCoviione 3-8 months after